LivaNova PLC (LIVN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LivaNova PLC (LIVN) has a cash flow conversion efficiency ratio of 0.074x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($85.06 Million) by net assets ($1.16 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
LivaNova PLC - Cash Flow Conversion Efficiency Trend (1992–2024)
This chart illustrates how LivaNova PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read LIVN total debt and obligations for a breakdown of total debt and financial obligations.
LivaNova PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LivaNova PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
0.053x |
|
Enaex S.A
SN:ENAEX
|
0.103x |
|
Shanghai Zhonggu Logistics Co Ltd
SHG:603565
|
0.064x |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
-0.012x |
|
Sprott Inc.
TO:SII
|
0.144x |
|
Huber+suhner AG
SW:HUBN
|
0.100x |
|
China Petroleum Engineering Corp
SHG:600339
|
-0.077x |
|
Autel Intelligent Technology Corp Ltd
SHG:688208
|
0.008x |
Annual Cash Flow Conversion Efficiency for LivaNova PLC (1992–2024)
The table below shows the annual cash flow conversion efficiency of LivaNova PLC from 1992 to 2024. For the full company profile with market capitalisation and key ratios, see how much is LivaNova PLC worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.32 Billion | $183.04 Million | 0.139x | +136.44% |
| 2023-12-31 | $1.28 Billion | $74.91 Million | 0.059x | +1.30% |
| 2022-12-31 | $1.21 Billion | $69.90 Million | 0.058x | -26.92% |
| 2021-12-31 | $1.29 Billion | $102.54 Million | 0.079x | +210.66% |
| 2020-12-31 | $1.11 Billion | $-79.40 Million | -0.072x | -8.67% |
| 2019-12-31 | $1.38 Billion | $-91.14 Million | -0.066x | -182.20% |
| 2018-12-31 | $1.50 Billion | $120.50 Million | 0.080x | +59.33% |
| 2017-12-31 | $1.82 Billion | $91.30 Million | 0.050x | -4.82% |
| 2016-12-31 | $1.71 Billion | $90.20 Million | 0.053x | +20.14% |
| 2015-12-31 | $1.81 Billion | $79.68 Million | 0.044x | -78.97% |
| 2014-12-31 | $259.10 Million | $54.20 Million | 0.209x | 0.00% |
| 2013-12-31 | $259.10 Million | $54.20 Million | 0.209x | -39.26% |
| 2012-12-31 | $229.57 Million | $79.05 Million | 0.344x | -15.79% |
| 2011-12-31 | $183.47 Million | $75.03 Million | 0.409x | +43.86% |
| 2010-12-31 | $175.45 Million | $49.87 Million | 0.284x | +14.84% |
| 2009-12-31 | $173.27 Million | $42.89 Million | 0.248x | -0.61% |
| 2008-12-31 | $98.74 Million | $24.59 Million | 0.249x | -73.03% |
| 2007-12-31 | $15.65 Million | $14.46 Million | 0.923x | -33.88% |
| 2006-12-31 | $-14.81 Million | $-20.69 Million | 1.397x | +109.12% |
| 2005-12-31 | $4.63 Million | $-70.88 Million | -15.308x | -29052.47% |
| 2004-12-31 | $75.60 Million | $-3.97 Million | -0.053x | -200.75% |
| 2003-12-31 | $68.98 Million | $3.60 Million | 0.052x | +175.46% |
| 2002-12-31 | $67.42 Million | $1.28 Million | 0.019x | +103.55% |
| 2001-12-31 | $43.02 Million | $-22.95 Million | -0.533x | -77.18% |
| 1999-12-31 | $27.15 Million | $-8.18 Million | -0.301x | +31.59% |
| 1998-12-31 | $33.40 Million | $-14.70 Million | -0.440x | -9.73% |
| 1997-12-31 | $36.90 Million | $-14.80 Million | -0.401x | -63.11% |
| 1996-12-31 | $48.80 Million | $-12.00 Million | -0.246x | +96.16% |
| 1995-12-31 | $1.50 Million | $-9.60 Million | -6.400x | -600.95% |
| 1994-12-31 | $6.90 Million | $-6.30 Million | -0.913x | -201.63% |
| 1993-12-31 | $18.50 Million | $-5.60 Million | -0.303x | -51.98% |
| 1992-12-31 | $24.10 Million | $-4.80 Million | -0.199x | -- |
About LivaNova PLC
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing syste… Read more